Oral Abstract Session 01 - Global HIV Vaccine Enterprise
Oral Abstract Session 01 - Global HIV Vaccine Enterprise
Oral Abstract Session 01 - Global HIV Vaccine Enterprise
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
CONFERENCE ORGANIZERS<br />
Conference Organizers<br />
Review Committee (cont.)<br />
Josephine Cox<br />
International AIDS <strong>Vaccine</strong> Initiative, USA<br />
Daniel Douek<br />
National Institutes of Health, USA<br />
Keith Fowke<br />
University of Manitoba, Canada<br />
Jonathan Fuchs<br />
San Francisco Department of Public Health, USA<br />
Paul Goepfert<br />
Department of Medicine, University of Alabama at<br />
Birmingham, USA<br />
Barney Graham<br />
<strong>Vaccine</strong> Research Center, National Institute of Allergy and<br />
Infectious Diseases, National Institutes of Health, USA<br />
Tomas Hanke<br />
University of Oxford, UK<br />
Alexandre Harari<br />
Centre Hospitalier Universitaire Vaudois, Lausanne University<br />
Hospital, Switzerland<br />
Shiu-Lok Hu<br />
University of Washington, USA<br />
Eric Hunter<br />
Emory University, USA<br />
Stephen Kent<br />
University of Melbourne, Australia<br />
Roger Le Grand<br />
CEA, France<br />
David Margolis<br />
University of North Carolina at Chapel Hill, USA<br />
Margaret Juliana McElrath<br />
Fred Hutchinson Cancer Research Center, USA<br />
James McIntyre<br />
Anova Health Institute, South Africa<br />
Andrew McMichael<br />
University of Oxford, UK<br />
Nelson Michael<br />
U.S. Military <strong>HIV</strong> Research Program, USA<br />
Chris Milller<br />
University of California Davis, USA<br />
David Montefiori<br />
Duke University Medical Center, USA<br />
Lynn Morris<br />
National Institute for Communicable Diseases, South Africa<br />
Gary Nabel<br />
<strong>Vaccine</strong> Research Center, National Institute of Allergy and<br />
Infectious Diseases, National Institutes of Health, USA<br />
Conference Secretariat<br />
<strong>Global</strong> <strong>HIV</strong> <strong>Vaccine</strong> <strong>Enterprise</strong>, USA<br />
Conference Solutions, USA<br />
Meeting Planner<br />
iv<br />
AIDS <strong>Vaccine</strong> 2<strong>01</strong>2<br />
Jo-Ann Passmore<br />
University of Cape Town, South Africa<br />
Harriet Robinson<br />
GeoVax, Inc., USA<br />
Nina Russell<br />
Bill & Melinda Gates Foundation, USA<br />
Eric Sandström<br />
Karolinska Institutet, Sweden<br />
Gabriella Scarlatti<br />
San Raffaele Scientific Institute, Italy<br />
Alexandra Schuetz<br />
U.S. Army Medical Component of the Armed Forces Research<br />
Institute of Medical Sciences, USA<br />
Olivier Schwartz<br />
Institut Pasteur, France<br />
Robin Shattock<br />
Imperial College, London, UK<br />
Guido Silvestri<br />
Emory University and Yerkes National Primate Research<br />
Center, USA<br />
Ronald Swanstrom<br />
University of North Carolina at Chapel Hill, USA<br />
Jim Tartaglia<br />
Sanofi Pasteur, USA<br />
Amalio Telenti<br />
Centre Hospitalier Universitaire Vaudois, Lausanne University<br />
Hospital, Switzerland<br />
Caroline Tanya Tiemessen<br />
National Institute for Communicable Diseases, South Africa<br />
Georgia Tomaras<br />
Duke Human <strong>Vaccine</strong> Institute, Duke University, USA<br />
Alexandra Trkola<br />
Institute of Medical Virology, University of Zurich, Switzerland<br />
Yegor Voronin<br />
<strong>Global</strong> <strong>HIV</strong> <strong>Vaccine</strong> <strong>Enterprise</strong>, USA<br />
Anna-Lise Williamson<br />
University of Cape Town, South Africa<br />
Susan Zolla-Pazner<br />
New York University School of Medicine, USA<br />
Michael Zwick<br />
The Scripps Research Institute, USA
Change language